AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A pharmaceutical composition for the treatment ~~or prophylaxis~~ of ~~a viral infection~~ human retroviral and hepatitis B viral infections comprising a compound of formula (I)



or a pharmaceutically acceptable salt thereof;

and at least one antiviral active compound of formula (II)



~~II~~



II

wherein said Base is selected from the group consisting of: thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

2. (Original) The pharmaceutical composition according to claim 1 wherein the compound of formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

3. (Original) The pharmaceutical composition according to claim 1 wherein the compound of formula (II) is 2',3'-dideoxy-3'-fluoroguanosine (FLG) or a pharmaceutically acceptable salt or prodrug thereof.

4. (Original) The pharmaceutical composition according to claim 1 wherein the compound of formula (II) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

5. (Cancelled)

6. (Original) The pharmaceutical composition according to claim 1 wherein the compound of formula (I) and the compound of formula (II) are present in a ratio between about 1:250 to about 250:1.

7. (Original) The pharmaceutical composition according to claim 1 further comprising ritonavir.

8. (Original) The pharmaceutical composition according to claim 1 further comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

9. (Original) The pharmaceutical composition according to claim 7 further comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

10. (Original) The pharmaceutical composition according to claim 1 further comprising a protease inhibitor.

11. (Original) The pharmaceutical composition according to claim 1 further comprising an entry inhibitor.

12. (Original) The pharmaceutical composition according to claim 10 further comprising an entry inhibitor.

13. (Original) The pharmaceutical composition according to claim 10 further comprising an integrase inhibitor.

14. (Original) The pharmaceutical composition according to claim 10 further comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

15. (Original) The pharmaceutical composition according to claim 11 further comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

16. (Original) The pharmaceutical composition according to claim 12 further comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

17. (Original) The pharmaceutical composition according to claim 13 further comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

18. (Original) The pharmaceutical composition according to claim 1 further comprising an antiviral agent selected from the group consisting of: maturation inhibitors, antisense compounds, and non-nucleoside reverse transcriptase inhibitor (NNRTIs).

19. (Original) The pharmaceutical composition according to claim 18 wherein the antiviral agent is selected from the group consisting of: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, lopinavir, delavirdine, delavirdine mesylate, nevirapine, delavirdine, efavirenz, indinavir, nelfinavir, nelfinavir mesylate, amprenavir, saquinavir, and saquinavir mesylate.

20. (Original) The pharmaceutical composition according to claim 1 further comprising a pharmaceutical carrier.

21. (Withdrawn) A method for the prophylaxis or treatment of a viral infection in a patient comprising administering a compound of formula (I)



or a pharmaceutically acceptable salt thereof, in combination or alternation with

at least one antiviral active compound of formula (II)



II

wherein said Base is selected from the group consisting of: thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

22. (Withdrawn) The method according to claim 21 wherein the compound of formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

23. (Withdrawn) The method according to claim 21 wherein the compound of formula (II) is 2',3'-dideoxy-3'-fluoroguanosine (FLG) or a pharmaceutically acceptable salt or prodrug thereof.

24. (Withdrawn) The method according to claim 21 wherein the compound of formula (II) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

25. (Withdrawn) The method according to claim 21 further comprising administering a protease inhibitor.

26. (Withdrawn) The method according to claim 21 further comprising administering an entry inhibitor.

27. (Withdrawn) The method according to claim 25 further comprising administering an entry inhibitor.

28. (Withdrawn) The method according to claim 25 further comprising administering an integrase inhibitor.

29. (Withdrawn) The method according to claim 25 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

30. (Withdrawn) The method according to claim 26 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

31. (Withdrawn) The method according to claim 27 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

32. (Withdrawn) The method according to claim 28 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

33. (Withdrawn) The method according to claim 21 further comprising administering an antiviral agent selected from the group consisting of: maturation inhibitors, antisense compounds, and non-nucleoside reverse transcriptase inhibitor (NNRTIs).

34. (Withdrawn) The method according to claim 33 wherein the antiviral agent is selected from the group consisting of: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, lopinavir, delavirdine, delavirdine mesylate, nevirapine, delavirdine, efavirenz, indinavir, nelfinavir, nelfinavir mesylate, amprenavir, saquinavir, and saquinavir mesylate.

35. (Withdrawn) The method according to claim 21 wherein the viral infection is a human retroviral infection (HRV).

36. (Withdrawn) The method according to claim 21 wherein the viral infection is a multiresistant human immunodeficiency virus (HIV) infection.

37. (Withdrawn) The method according to claim 35 wherein perinatal transmission of the human retroviral (HRV) infection from mother to baby is prevented.

38. (Withdrawn) The method according to claim 21 wherein the compound of formula (I) and the compound of formula (II) are administered to the patient in combination or alternation in a synergistic ratio.

39. (Withdrawn) The method according to claim 21 wherein the compound of the formula (I) and the compound of the formula (II) are administered to the patient in combination or alternation in a ratio between about 1:250 to about 250:1.

40. (Withdrawn) The method according to claim 21 wherein the compound of formula (I) is administered in combination with ritonavir and in combination or alternation with said compound of formula (II).

41. (Withdrawn) The method according to claim 21 further comprising administering a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof in combination or alternation.

42. (Currently Amended) A kit of parts for the ~~prophylaxis or~~ treatment of ~~a viral infection~~ human retroviral and hepatitis B viral infections in a patient, comprising:
    (a) a first containment containing a pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and
    (b) a second containment containing a pharmaceutical composition comprising an antiviral active compound of formula (II) according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier.

43. (Original) The kit of parts according to claim 42, wherein the compound of formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

44. (Original) The kit of parts according to claim 42, wherein the compound of formula (II) is 2',3'-dideoxy-3'-fluoroguanosine (FLG) or a pharmaceutically acceptable salt or prodrug thereof.

45. (Original) The kit of parts according to claim 42, wherein the compound of formula (II) is 3'-deoxy-3'-fluoro-5-O-[2-(L-valyloxy)-propionyl]guanosine or a pharmaceutically acceptable salt thereof.

46. (Original) The kit of parts according to claim 42 further comprising a containment containing a pharmaceutical composition comprising ritonavir.

47. (Original) The kit of parts according to claim 42 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

48. (Original) The kit of parts according to claim 42 further comprising a containment containing a pharmaceutical composition comprising a protease inhibitor.

49. (Original) The kit of parts according to claim 42 further comprising a containment containing a pharmaceutical composition comprising an entry inhibitor.

50. (Original) The kit of parts according to claim 48 further comprising a containment containing a pharmaceutical composition comprising an entry inhibitor.

51. (Original) The kit of parts according to claim 48 further comprising a containment containing a pharmaceutical composition comprising an integrase inhibitor.

52. (Original) The kit of parts according to claim 48 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

53. (Original) The kit of parts according to claim 49 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

54. (Original) The kit of parts according to claim 50 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

55. (Original) The kit of parts according to claim 51 further comprising a containment containing a pharmaceutical composition comprising a further nucleoside reverse transcriptase inhibitor (NRTI), or a pharmaceutically acceptable salt or prodrug thereof.

56. (Original) The kit of parts according to claim 42 further comprising a containment containing a pharmaceutical composition comprising an antiviral agent selected from the group consisting of: maturation inhibitors, antisense compounds, and non-nucleoside reverse transcriptase inhibitors (NNRTIs).

57. (Original) The kit of parts according to claim 56 wherein the antiviral agent is selected from the group consisting of: zidovudine, didanosine, zalcitabine, stavudine, lamivudine, lopinavir, delavirdine, delavirdine mesylate, nevirapine, delavirdine, efavirenz, indinavir, nelfinavir, nelfinavir mesylate, amprenavir, saquinavir, and saquinavir mesylate.